Pasithea Therapeutics (KTTA) Revenue (2022)

Pasithea Therapeutics recorded quarterly Revenue of $240712.0 in Q4 2022, up 10.11% quarter-over-quarter from $218608.0 in Q3 2022.

Pasithea Therapeutics' Revenue history runs 1 years deep, the most recent figure standing at $240712.0 for Q4 2022.

  • In Q4 2022, Revenue changed N/A year-over-year to $240712.0; the TTM figure through Dec 2022 stood at $486559.0 (changed N/A YoY), while the FY2022 annual figure was $486559.0, up 3130.37% from the prior year.
  • Revenue came in at $240712.0 for Q4 2022 at Pasithea Therapeutics, up from $218608.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $240712.0 in Q4 2022 to a low of $13581.0 in Q2 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 306.30 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 2.99 Bn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 3.61 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 1.17 Bn
10 Pasithea Therapeutics 17.41 Mn 17.41 Mn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2022 240,712.00
Sep 30, 2022 218,608.00
Jun 30, 2022 13,581.00
Mar 31, 2022 13,658.00